Press Releases Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development Oct 28, 2026 Coherus to Participate in Upcoming Investor Conferences Oct 27, 2026 Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 Oct 26, 2026 Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 Oct 14, 2026 Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets Sep 23, 2026 Coherus to Participate in Upcoming Investor Conferences Aug 31, 2026 Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights Aug 17, 2026 Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 05, 2026 Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 Jul 22, 2026 Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) Jun 23, 2026
Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development Oct 28, 2026 Coherus to Participate in Upcoming Investor Conferences Oct 27, 2026 Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 Oct 26, 2026 Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 Oct 14, 2026 Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets Sep 23, 2026 Coherus to Participate in Upcoming Investor Conferences Aug 31, 2026 Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights Aug 17, 2026 Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 05, 2026 Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 Jul 22, 2026 Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) Jun 23, 2026
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development Oct 28, 2026
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 Oct 14, 2026
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 05, 2026
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) Jun 23, 2026
